Key facts
- Employers are implementing stricter rules for GLP-1 weight-loss drug approvals.
- New requirements include mandatory weigh-ins.
- App tracking is now a common requirement for coverage.
- Health coaching is also part of the new approval criteria.
- Some companies are considering removing coverage for these drugs entirely.
- These changes are driven by rising costs associated with GLP-1 medications.
Employers are responding to the escalating costs of GLP-1 weight-loss drugs by implementing stricter approval requirements. These new measures aim to control spending on medications like Ozempic and Wegovy, which have seen a surge in demand for weight management. Common stipulations now include mandatory weigh-ins to verify ongoing weight loss, the use of health and fitness tracking apps, and participation in health coaching programs. These steps are designed to ensure the drugs are being used effectively for their intended purpose and to justify the significant expense. In some cases, companies are going further and considering the complete discontinuation of coverage for these GLP-1 medications altogether. This move reflects a growing concern among employers about the long-term financial implications of covering these high-cost treatments, especially as more employees seek access. The trend indicates a broader reevaluation of drug coverage policies within employer-sponsored health plans, particularly for innovative but expensive therapies.